Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617

Molecular Imaging and Biology

Volumn 18, Issue 3, 2016, Pages 437-445

  Hohberg, Melanie ^a   Eschner, Wolfgang ^a   Schmidt, Matthias ^a   Dietlein, Markus ^a   Kobe, Carsten ^a   Fischer, Thomas ^a   Drzezga, Alexander ^a   Wild, Markus ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Dosimetry; Lacrimal glands; Prostate cancer; PSMA; Radioligand radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DKFZ PSMA 617 LU 177; RADIOISOTOPE; UNCLASSIFIED DRUG; 177LU-DKFZ-PSMA-617; ORGANOMETALLIC COMPOUND;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; KIDNEY; LACRIMAL GLAND; MALE; NOSE MUCOSA; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SALIVARY GLAND; CHEMISTRY; DEMOGRAPHY; DIAGNOSTIC IMAGING; LACRIMAL APPARATUS; MIDDLE AGED; ORGANS AT RISK; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; TIME FACTOR; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

AGED; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LACRIMAL APPARATUS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANS AT RISK; PROSTATIC NEOPLASMS; TIME FACTORS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84971280576     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-016-0942-0     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
2. Zechmann CM, Afashar-Oromieh A, Armor T et al (2014) Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292
3. Bacich DJ, Pinto JT, Tong WP, Heston WD (2001) Cloning expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 12:117–123
4. Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer. Hum Pathol 38:696–701
5. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM (2006) Molecular markers of prostate cancer. Urol Oncol 24:538–551
6. Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591–4601
7. Foss CA, Mease RC, Fan H et al (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022–4028
8. Humblet V, Lapidus R, Williams LR et al (2005) High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 4:448–462
9. Pomper MG, Musachio JL, Zhang J et al (2002) 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 1:96–101
10. Eder M, Schafer M, Bauder-Wust U et al (2012) 68Ga-complex lipophilicity and targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697
11. Afshar-Oromieh A, Haberkorn U, Hadaschik B et al (2013) PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 40:1629–1630
12. Eiber M, Nekolla SG, Maurer T et al (2014) Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging 40:1769–1771
13. Tasch J, Gong M, Sadelain M, Heston WD (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 21:249–261
14. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 42:987–988
15. Bé MM, Chisté V, Dulie C, et al (2004) Table of radionuclides (Vol. 2-A = 151 to 242). Bureau international des poids et mesures, Pavillon de Breteuil, Sèvres
16. Hindorf C, Glatting G, Chiesa C, Lindén O et al (2010) EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Med Mol Imgaging 37:1238–1250
17. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027
18. Snyder WS, Fischer HL Jr, Ford MR, Warner GG (1969) Estimate of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD pamphlet no. 5. J Nucl Med 10:7–52
19. Loevinger R, Budinger TF, Watson EE (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York
20. Snyder WS, Cook MJ, Nasset ES, et al (1979) Report of the task group on reference man. ICRP Publication 23
21. Bukhari AA, Basheer NA, Joharjy HI (2014) Age, gender and interracial variability of normal lacrimal gland volume using MRI. Ophthal Plast Reconstr Surg 30:388–391
22. Bingham CM, Castro A, Realini T et al (2013) Calculated CT volumes of lacrimal glands in normal Caucasian orbits. Ophthal Plast Reconstr Surg 29:157–159
23. Garkavij M, Nickel M, Sjögreen-Gleisner K et al (2010) 177Lu-[DOTA0, Tyr3] Octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 116:1084–1092
24. Sandström M, Garske U, Granberg D et al (2010) Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging 37:212–225
25. Delker A, Fendler WP, Kratochwil C et al (2016) Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43:42–51
26. Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176
27. Pandit-Taskar N, O’Donoghue JA, Durack JC et al (2015) A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res 21:5277–5285
28. Banerjee SR, Foss CA, Castanares M et al (2008) Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 51:4504–4517
29. Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 68:530–534
30. Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914–920
31. Ahmadzadehfar H, Rahbar K, Kurpig S et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. doi:10.1186/s13550-015-0114-2
32. Pfestroff A, Luster M, Jilg CA et al (2015) Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging 42:1971–1975
33. Parsons JT, Bova FJ, Mendenhall WM et al (1996) Response of the normal eye to high dose radiotherapy. Oncology 10:837–847
34. Buchali A, Schröder C, Sidow D, Blank E (1991) Influence of the radiation dose to salivary glands on xerostomia in patients with head and neck carcinomas. J Cancer Ther 4:188–194
35. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122
36. Yin G, Xiong G, Zhao C, Chen Y (2010) Damage of nasal mucociliary movement after intensity-modulated radiation therapy of nasopharyngeal carcinoma. Chin J Cancer 29:824–829
37. 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. doi:10.1186/2191-219X-2-49
38. Siegel JA, Thomas SR, Stubbs JB et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S–61S